about
Sample preparation techniques for the untargeted LC-MS-based discovery of peptides in complex biological matricesNeuropeptides in depression: role of VGFThe role of the vgf gene and VGF-derived peptides in nutrition and metabolismVGF changes during the estrous cycle: a novel endocrine role for TLQP peptides?Rapid etiological classification of meningitis by NMR spectroscopy based on metabolite profiles and host responseHuman body fluid proteome analysis.Prion disease diagnosis by proteomic profiling.Glycoproteomics in neurodegenerative diseases.Proteomic analysis of HIV-infected macrophagesBiomarker discovery in neurodegenerative diseases: a proteomic approach.Peptidome analysis of cerebrospinal fluid by LC-MALDI MSInvestigation and reduction of sub-microgram peptide loss using molecular weight cut-off fractionation prior to mass spectrometric analysis.Separation of biological proteins by liquid chromatography.Biomarkers in chronic adult hydrocephalus.Proteomics of gliomas: initial biomarker discovery and evolution of technology.Rapid synthesis of titanium(IV)-immobilized magnetic mesoporous silica nanoparticles for endogenous phosphopeptides enrichment.Biomarkers for amyotrophic lateral sclerosis.Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseasesPlant peptides and peptidomics.Psychiatric research: psychoproteomics, degradomics and systems biology.Mass spectrometry-based neurochemical analysis: perspectives for primate research.NPAS3 Regulates Transcription and Expression of VGF: Implications for Neurogenesis and Psychiatric Disorders.Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery.The regulation of brain states by neuroactive substances distributed via the cerebrospinal fluid; a review.Proteomic profiling of cerebrospinal fluid in Creutzfeldt-Jakob disease.Proteomic analysis of prion diseases: creating clarity or causing confusion?Human Antimicrobial Peptides in Bodily Fluids: Current Knowledge and Therapeutic Perspectives in the Postantibiotic Era.A novel approach for characterizing variations in serum peptides in rheumatic heart disease.Multiple isotopic labels for quantitative mass spectrometry.A preliminary study of metalloproteins in CSF by CapLC-ICPMS and NanoLC-CHIP/ITMS.Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease.Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid.Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications.
P2860
Q21296806-258361CD-20B1-486B-B3D5-CD69515AEE7FQ24647788-F8A9A734-1D35-4D62-8A77-3A90679F6892Q24657048-0DADA45A-0B26-4BA7-A2C0-62330C210CB1Q27343928-4BB0C5C2-EA45-46F7-B8BE-931104FBD1ADQ28475384-1BB612C0-CDAD-409A-BC33-FA0F545CDCC3Q33262623-E9CDD5AB-5069-440D-B330-11FC308FCCFDQ33398738-C66A4C2A-3820-48D0-A4A6-A55624E83F95Q33563387-F722BCD1-3E4D-4709-AC7D-395BB2874356Q33770687-06D17426-1594-497A-8518-D917595E9F12Q34125681-20F7FFC9-66F9-45A1-820C-3332DD6F20FDQ34374324-58151F8F-67F4-473C-BC7E-0876ECCCEF05Q34423522-6C301CA4-D2CB-48A2-9C56-A2007B14F7A6Q34957698-053B8F77-0BF7-425A-A4FD-28E79DE6514EQ35101048-6E60CBE1-1185-43F0-A7CB-EC296127DDBCQ35170365-74612BBB-47BD-4CE0-9DAF-3C0AB8E078C1Q36270602-66E80B19-8380-4778-902C-ED83701ED58FQ36481118-93B4013D-F192-400B-9A45-F3545E737658Q36615226-DBA87F65-FAC9-4E82-A429-DEAC341EB81BQ36657393-16502F7D-3D37-48D3-8E3B-B2505B204931Q36974613-CFA65F88-C79E-4073-9DB0-47B731504ECEQ37028228-9B7EF8C3-8A3B-4CE0-810B-1ED6A709B1FCQ37157851-07A3A0E0-B1EA-4A25-AF2D-93AFCD15529FQ37304110-FF4A4468-02F8-42FA-A9E0-275316922E64Q37399106-A57648C9-B6A5-49CE-BDFB-AEA31989300BQ37552845-EA140391-41DF-441D-AA02-8B65D73BD6A9Q37692949-162F30C8-A3A4-47A6-994E-A4F631B87628Q37818319-2E104D4D-C15C-4D50-BD91-58EB797FE053Q38060590-90594C94-C428-4593-8E45-4EA60DADB5E6Q39091774-E5398621-A68E-4C39-A589-88E420D468E7Q40045948-8BE55443-979A-4133-B160-C9D50AF78FDCQ41832101-CFBFB742-8971-4F4D-93D7-F875EB4E0C53Q43093029-4B6D04BB-6149-437A-9BAF-B9AE01ACBC21Q46938051-93F5757F-7A44-4D57-A122-B37845ACDAF1Q47245866-1F1FDD8F-7D16-46E4-82AF-CB2F20A070DCQ47763379-5C1C5A93-AFA7-4DE0-9923-5592B890313A
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Human cerebrospinal fluid peptidomics
@ast
Human cerebrospinal fluid peptidomics
@en
Human cerebrospinal fluid peptidomics
@en-gb
Human cerebrospinal fluid peptidomics
@nl
type
label
Human cerebrospinal fluid peptidomics
@ast
Human cerebrospinal fluid peptidomics
@en
Human cerebrospinal fluid peptidomics
@en-gb
Human cerebrospinal fluid peptidomics
@nl
prefLabel
Human cerebrospinal fluid peptidomics
@ast
Human cerebrospinal fluid peptidomics
@en
Human cerebrospinal fluid peptidomics
@en-gb
Human cerebrospinal fluid peptidomics
@nl
P3181
P356
P1476
Human cerebrospinal fluid peptidomics
@en
P2093
Dominic M Desiderio
Xianglin Yuan
P304
P3181
P356
10.1002/JMS.737
P407
P577
2005-02-01T00:00:00Z